Publication Topic

Sacks NC, Everson K, Cyr PL, Emden M, Preib M, Wood D, Pokorney S. Variations in healthcare resource use and expenditures by age in patients under Age 65 newly diagnosed with paroxysmal supraventricular tachycardia (PSVT) in the United States. ISPOR 24th Annual International Meeting, New Orleans LA, 2019.

Malone D, Miller B, Dean R, Arjunji R, Jensen IS, Maru B, Dabbous O. 2019. Abstract PRO10: Use of single dose gene-replacement therapy for the treatment of spinal muscular atrophy type 1: A United States payer budget impact analysis. Value in Health 22(Sup2):S336-S337; doi: 10.1016/j.jval.2019.04.1644.

Malone DC, Dean R, Miller B, Arjunji R, Feltner DE, Sproule D, Jensen IS, Maru B, Dabbous O. 2019. Abstract ND2: Cost-utility analysis of single dose gene-replacement therapy for spinal muscular atrophy type 1 compared to chronic nusinersen treatment. Value in Health 22(Sup 2):S42-S43; doi: 10.1016/j.jval.2019.04.060.

Arjunji R, Dean R, Jensen IS, Miller B, Menier M, Sproule DM, Feltner DE, Droege M, et al. 2019. Abstract PBI10: Type I spinal muscular atrophy patients treated with AVXS-101 have lower use of ventilatory support, hospitalization, and associated costs compared to those treated with nusinersen. Value in Health 22(Sup 2):S48; doi: 10.1016/j.jval.2019.04.093.

Su J, Bylsma LC, Jiang X, Morales Arias J, Jain N, Nordyke RJ. Healthcare resource utilization among commercially insured cold agglutinin disease patients in the United States. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research, New Orleans, LA, May 2019.

Sacks NC, Cyr PL, Green S, Wood D, Pokorney S. Healthcare resource use and costs following catheter ablation in paroxysmal supraventricular tachycardia (PSVT) patients age <65. Podium presentation, International Society for Pharmacoeconomics and Outcomes Research. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, New Orleans, LA, May 2019.

Malone DC, Dean R, Arjunji R, Jensen IS, Cyr PL, Miller B, Maru B, et al. 2019. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Pol 7(1):1601484; doi: 10.1080/20016689.2019. PMID: 31105909.

Sacks NC, Everson K, Cyr PL, Wood DR, Pokorney SD. Variations in healthcare resource use and expenditures in younger women and men newly diagnosed with paroxysmal supraventricular tachycardia (PSVT) in the United States. Poster presentation, American Heart Association/American Stroke Association Quality of Care and Outcomes Research (QCOR) Annual Meeting, Washington, DC, April 2019.

Preib M, Pokorney SD, Cyr PL, Everson K, Wood D, Sacks NC. Demographics and clinical characteristics of patients newly diagnosed with paroxysmal supraventricular tachycardia (PSVT). Poster presentation at European Heart Rhythm Society, Lisbon, Portugal, March 2019.

Brixner D, Ermakova A, Xiong Y, Sieradzan R, Sacks NC, Cyr PL, Taylor S. 2019. Clinical and economic outcomes of patients with type 2 diabetes on multiple daily injections of basal-bolus insulin (MDI) therapy: A retrospective cohort study. Clin Therapeut 41(2):303–313; doi: 10.1016/j.clinthera.2018.12.014; PMID: 30709610.

Frankenfeld CL, Menon N, Leslie TF. Racial disparities in colorectal cancer time-to-surgery and survival time associated with diagnosing hospital cancer-related diagnostic and treatment capabilities in Georgia. Presentation to American Public Health Association, 2019.

Bylsma LC, Reichert H, Gage SM, Roy-Chaudhury P, Nordyke RJ, Fryzek J, Dahl SLM, Lithgow T, Lawson JH. 2019. Clinical outcomes of arteriovenous access in incident hemodialysis patients with Medicare coverage, 2012–2014. Am J Nephrol 49(2):156–164; doi: 10.1159/000495355. PMID: 30677763.

Sacks NC. Evaluating clinical and economic burden of paroxysmal supraventricular tachycardia (PSVT) using real world evidence. Podium presentation, Real World Data and Life Science Analytics Congress. Boston, MA, October 2018.

Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, et al. 2018. Patterns of bicalutamide use in prostate cancer treatment: A U.S. real-world analysis using the SEER-Medicare database. Adv Ther 35(9):1438-1451; doi: 10.1007/s12325-018-0738-5. PMID: 29946798.

Ludden T, Ermakova A, Xiong Y, Cyr PL, Sieradzan R, Sacks NC, Taylor SD. Comparison of healthcare resource utilization for multiple-daily injections (MDI) with basal and bolus insulin therapy versus non-MDI therapy in patients with Type 2 diabetes. Poster presentation at Academy of Managed Care Pharmacy Annual Research Meetings, Boston, MA, 2018.

Ludden T, Ermakova A, Xiong Y, Cyr PL, Sieradzan R, Sacks NC, Taylor SD. Comparison of healthcare resource utilization and clinical status among Type 2 diabetes patients using multiple-daily injection (MDI) insulin therapy vs. non-MDI therapy. ISPOR 23^rd Annual Conference, Baltimore MD, 2018.

Sacks NC, Cyr PL, Bariahtaris S, Sharma A, Everson K, Douville P, Ruskin J. Healthcare resource use and expenditures in patients under 65 years of age and newly diagnosed with paroxysmal superventricular tachycardia (PSVT) in the United States. Podium Presentation at World Congress on Heart Disease, Boston MA, 2018.

Jensen IS, Wu E, Cyr PL, Claussen M, Winkler T, Salhuddin K, Prats J, et al. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention (PCI) patients: A US hospital perspective. Transcatheter Cardiovascular Therapeutics (TCT), San Diego, CA, 2018.

Hathway J, Purdum AG, Lin VW, Cyr PL, Westin J, Jensen IS. A budget impact model of Axicabtagene Ciloleucil in a US population of patients with relapsed/refractory large B-cell lymphoma (RR-LBCL). European Blood and Marrow Transplantation Meeting, Lisbon Portugal, 2018.